Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

Texas MPN Workshop 2021 | Unmet needs for polycythemia vera treatment

Jerry Spivak, MD, Johns Hopkins University School of Medicine, Baltimore, MD, outlines the unmet needs for polycythemia vera by discussing the current diagnostic tools and their challenges, as well as issues faced by patients who develop post-polycythemia vera myelofibrosis, an aspect which existing JAK inhibitors and interferons fail to address. Prof. Spivak also comments on the impacts of using hydroxyurea as frontline therapy. This interview took place at the Texas MPN Workshop: Second Annual Workshop and Meeting in 2021.